Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis

Overview of attention for article published in Arthritis Research & Therapy, June 2016

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (66th percentile)
Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

twitter: 6 X users

Citations

dimensions_citation: 40 Dimensions

Readers on

mendeley: 76 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 33,664 followers.

@baeles2 Dentro de lo que es la especialidad, la evidencia no es tan mala. Es por lo menos tan efectivo como la ciclofosfamida ora, quizás mejor, pero definitivamente menos tóxico https://t.co/RLqRECle6Q https://t.co/4XgIXe935h

02 Feb 2021

Reply Repost Favourite

RT @reumacia: Estudios CFM versus MFM en afectación intersticial pulmonar de #esclerodermia https://t.co/ajL4u3JUeh https://t.co/2ulJm8PVrL…

15 Oct 2016

Reply Repost Favourite

Estudios CFM versus MFM en afectación intersticial pulmonar de #esclerodermia https://t.co/ajL4u3JUeh https://t.co/2ulJm8PVrL #Reumatopics16

14 Oct 2016

Reply Repost Favourite

RT @Sklerodermie4U: 6 Monate Therapie der #Sklerodermie mit Lungenfibrose: Mycophenolat mofetil und Cyclophosphamid vergleichbar wirksam ht…

09 Jun 2016

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.